
Keywords: Angiotensin-converting enzyme (ACE) inhibitor; angiotensin II receptor blocker (ARB); renin angiotensin system (RAS) inhibition; chronic kidney disease (CKD); kidney failure; cardiovascular events; mortality; all-cause death; renal disease progression; bl